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Abstract Hypoglycaemia is a major cause of neonatal
morbidity and may induce long-term developmental
sequelae. Clinical signs of hypoglycaemia in neonatal
infants are unspecific or even absent, and therefore, precise
and accurate methods for the assessment of glycaemia are
needed. Glycaemia measurement in newborns has some
particularities like a very low limit of normal glucose
concentration compared to adults and a large range of
normal haematocrit values. Many bedside point-of-care
testing (POCT) systems are available, but literature about
their accuracy in newborn infants is scarce and not very
convincing. In this retrospective study, we identified over a
1-year study period 1,324 paired glycaemia results, one
obtained at bedside with one of three different POCT
systems (Elite™ XL, Ascensia™ Contour™ and ABL 735)
and the other in the central laboratory of the hospital with
the hexokinase reference method. All three POCT systems
tended to overestimate glycaemia values, and none of them
fulfilled the ISO 15197 accuracy criteria. The Elite XL
appeared to be more appropriate than Contour to detect
hypoglycaemia, however with a low specificity. Contour
additionally showed an important inaccuracy with increas-
ing haematocrit. The bench analyzer ABL 735 was the most
accurate of the three tested POCT systems. Both of the
tested handheld glucometers have important drawbacks in
their use as screening tools for hypoglycaemia in newborn
infants. ABL 735 could be a valuable alternative, but the
blood volume needed is more than 15 times higher than for
handheld glucometers. Before daily use in the newborn
population, careful clinical evaluation of each new POCT
system for glucose measurement is of utmost importance.
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Abbreviations
POCT Point-of-care testing
Elite XL Glucometer Elite™ XL
Contour Ascensia® Contour® (5 s)
DAS Data acquisition system
NICU Neonatal Intensive Care Unit
Introduction
Blood glucose monitoring is part of standard care in
nurseries and neonatal intensive care units (NICU). Hypo-
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glycaemia is a major cause of neonatal morbidity and may
induce long-term developmental sequelae, especially when
happening repetitively [6, 19]. Therefore, rapid detection
and treatment of low glucose values is crucial. However,
clinical diagnosis of hypoglycaemia in neonates is a
challenge because symptoms are unspecific or completely
absent. Precise and accurate methods for rapid assessment
of glycaemia are a requisite for institutions taking care of
neonates. The hexokinase method, used as reference in this
study, is considered as gold standard for the quantification
of plasma glucose. This method, however, suffers several
drawbacks, like the delayed availability of the result due to
transport of the blood sample to the centralised laboratory
in distance from the NICU and the time needed to
centrifuge the blood sample before analysing it. A second
disadvantage is the need for a relatively large volume of
blood (typically 300 µL) in regards to the total blood
volume of 80–100 mL/kg body weight of newborn infants.
Thus, easy to use point-of-care testing (POCT) devices
performing measurements at bedside within seconds and
requiring small volumes of blood could be ideal alter-
natives, provided they give accurate results compared to the
reference method.
Over the past years, multiple portable glucose meters
have been developed and increasingly used in clinical
neonatal settings. Measurement of most of these devices is
based on an electrochemical reaction using either glucose
oxidase or glucose dehydrogenase. The numerous glucose
meters available on the market vary in regards to the
needed blood volume, their turnaround time (availability of
the result), the type of result presentation (whole blood or
plasma referenced), the need or not of strip lot calibration,
their sensitivity towards oxygen tension or haematocrit
values and their susceptibility to interference by various
substances like ascorbic acid, acetaminophen, dopamine,
paracetamol, mannitol, etc. [7, 18, 29, 31]. Portable glucose
meters were originally developed with the focus on adult
diabetic patients for self-testing. Compared to the high
number of different devices, literature about their use in
neonates remains limited and the results in most cases are
not very convincing [2, 9, 10, 15–17, 20–23, 25–28].
Glucose monitoring in newborn patients has some
specific characteristics: (1) Metabolic adaptation to postna-
tal life demands in many newborn patients repeated glucose
measurements in particular to screen for hypoglycaemic
values. Considering the small circulating blood volume in
neonates, methods for glucose measurement needing small
quantities of blood are of utmost importance. (2) In contrast to
older children and adults, the low limit of normal plasma
glucose in term newborn infants is very low, somewhere
between 1.6 and 2.7 mmol/L during postnatal days 1–3 [1].
The decision limit for treatment intervention is commonly
set at 2.5 mmol/L (45 mg/dL) [4]. (3) Haematocrit
potentially interferes with glucose measurement [7, 8, 18,
30]. Whereas in adults “normal blood” has a haematocrit
close to 43%, it may vary in neonates between 25% and
64% according to gestational and postnatal age and therefore
may decrease the accuracy of glucometers [14]. (4) The
naturally occurring hyperbilirubinaemia of the newborn
infant encompassing the adult normal limits by 10–15 times
may also potentially interfere with the measurement and
may reduce the POCT performance [7, 8, 11, 29].
In order to test the accuracy of a new handheld POCT
glucometer in neonates, we evaluated the Ascensia™
Contour™ (5-s measurement and FAD as coenzyme) in
the clinical environment of a NICU with neonates of a wide
variation of pathologies and gestational ages. The main
focus of this study was on the low glycaemic range.
Accuracy was judged by comparison with hexokinase
method obtained from the same capillary blood sampling.
An identical evaluation was undertaken with the older
generation of glucometer of the same company (Elite™
XL) and with the NICU-located bench POCT method, ABL
735, a blood gas analyser with a glucose electrode.
Additionally, we studied the influence of haematocrit.
Material and methods
Patients and sample selection
Our internal guidelines request that all glycaemia values
≤3.0 mmol/l measured with a POCT device need an
immediate double check with the hexokinase reference
method in the central laboratory. Furthermore, control
values by the reference method are generously demanded
when other chemistry exams are required, as long as no
supplementary blood is necessary. We therefore have quite
often the opportunity to compare glucose results of the
reference method with one of the POCT systems.
All patients hospitalised in the NICU are connected to a
data acquisition system (DAS; Metavision®, iMDsoft, Tel
Aviv, Israel) which records automatically every minute
clinical and laboratory data. Additionally, the nurses
introduce manually information about diagnostic and
treatment interventions (e.g. blood sampling). We thus
know exactly the timing of blood sampling in the NICU
and result validation in the central laboratory as well as the
results obtained by the different measurement methods. For
the period between December 2006 and December 2007,
the DAS allowed us to screen retrospectively 29,350 blood
glucose values. Our inclusion criteria were: paired glucose
values (first with one of the three POCT systems, second
with the reference method) performed in the blood sample
and registered in the DAS within <60 min. To reduce the
bias of different sampling locations and techniques, only
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capillary blood samples were selected [12]. A total of 1,324
paired samples, meaning 2,648 capillary blood glucose
values, were retained for analysis. The study was accepted
by the ethics committee of the University Hospital of
Lausanne, and no written consent was demanded.
Sampling method
Softasept® (B. Braun Medical AG, Sempach, Switzerland)
was used for disinfection and Accu-Chek® Softclix Pro
(Roche Diagnostics, Rotkreuz, Switzerland) for standard
heel puncture with reproducible puncture depth. After
drying and wiping off the first blood drop, blood
collection for glucose measurement was done in the
following order: (1) handheld glucometer (Elite XL or
Contour), (2) ABL 735 in a heparinised capillary if
blood gas analysis was demanded, (3) reference method
in a Microvette® CB 300 with lithium heparinate
or fluoride as anticoagulants (Sarstedt, Nümbrecht,
Germany).
Table 1 Characteristics of the three POCT meters
Elite XL Contour ABL 735
Official name Old name: Glucometer Elite™ XL Old name: Ascensia™
Contour™
ABL 735
New name: Ascensia Elite™ XL New name: Contour™
Company Bayer AG, Diabetes Care, Zurich,
Switzerland
Bayer AG, Diabetes Care,
Zurich, Switzerland
Radiometer, Copenhagen, Denmark
Approved for neonatal use during
study period
Yes (for control, but not for
diagnostic)
Yes Yes
Method of measurement Glucose oxidase-based amperometric
strip
FAD glucose dehydrogenase-
based amperometric strip
Amperometric electrode with glucose
oxidase membrane
Need for strip lot coding Yes No n/a
Type of sample Capillary blood Capillary blood Heparinized capillary blood
Volume of blood sample 2 μL 0.6 μL 35 μL if only glucose measurement
95 μL if together with blood
gas measurements
Analysis time 30 s 5 s 80 s (for 35 μL capillaries)
135 s (for 95 μL capillaries)
Test result Whole blood referenced Plasma referenced Plasma referenced
Test range 1.1–33.3 mmol/L 0.6–33.3 mmol/L 0–60 mmol/L
Haematocrit limits (%) 20–70% (neonatal use: for glucose
between 1.1 and 6.7 mmol/L)
0–70% No information
Internal quality control: Imprecision
at low glucose concentration
CV: 3.4% at 2.5 mmol/L CV: 2.1% at 2.4 mmol/L CV: 1.9% at 2.4 mmol/L
n/a not applicable, CV coefficient of variation
Table 2 Study demographics
Elite XL Contour ABL 735
Number of patients 132 157 133
Number of study samples 472 532 320
Number of samples/patient
Mean (± SD) 3.6 (±4.8) 3.4 (±4.2) 2.4 (±2.6)
Median (Range) 2 (1–34) 2 (1–30) 1 (1–16)
Reference glycemia (mmol/L)
Median (Range; mmol/L) 3.2 (0.1–15.9) 3.7 (0.1–23.6) 4.0 (0.1–17.7)
Mean (± SD in mmol/L) 4.1 (±2.45) 4.4 (±2.90) 4.6 (±2.75)
Number of samples with additional haematocrit 116 188 319
Haematocrit values (%)
Median (Range) 42.0 (26.0–72.1) 44.5 (26.3–74.7) 43.1 (23.9–74.7)
Mean (±SD) 44.3 (±9.9) 46.4 (±10.5) 45.3 (±10.2)
Eur J Pediatr (2010) 169:1387–1395 1389
Glucose measurements
During the first 6 months of the study period, we used
30 devices of the Elite XL and during the second
6 months the same number of devices of Contour. As a
third POCT system, we used over the whole study period
the blood gas analyser ABL 735, located in the NICU.
All nursing staff was well trained and experienced in the
use of the three POCT meters. The main characteristics
of the POCT systems as well as the day-to-day
imprecision in the low glucose range are summarised in
Table 1.
The reference method for plasma glucose measurement
in the central laboratory of the University Hospital of
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Fig. 1 Passing & Bablok
regression analysis between the
three POCT glucose meters and
the reference method: A-1, B-1,
C-1 Whole range of glycaemia
values; A-2, B-2, C-2 Focus on
low range glycaemia values
(≤5.0 mmol/L, measured by
reference method). Interrupted
line line of identity. Rectangular
striped area false negative
values with a cutoff of
2.5 mmol/L
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Lausanne is the hexokinase/glucose-6-phosphate dehydro-
genase method (Gluco-quant Glucose/HK method on a
Modular P system; Roche Diagnostics). This method,
which is standardised on the primary reference method by
isotope dilution mass spectrometry, is considered a second-
ary reference method by the National Committee for
Clinical Laboratory Standards [24]. The typical volume of
blood sample needed is 300 µL and the turnaround time to
the plasma glucose result is usually <1 h. During the whole
study period, day-to-day imprecision was 2.3% at
3.3 mmol/L and 2.2% at 20.1 mmol/L. Accuracy was
validated by participation to two external quality control
surveys (Quality Control Center, Switzerland; Reference
Institute for Bioanalytics, Germany).
ISO 15197 accuracy criteria
The International Organization for Standardization (ISO)
has defined accuracy criteria for point-of-care glucose
meters [13]. They request that 95% of all glycaemia results
on POCT systems do not differ by more than ±0.8 mmol/L
for glycaemia values ≤4.2 mmol/L or by more than ±20%
for glycaemia values >4.2 mmol/L compared to the results
measured by the reference method.
Haematocrit measurements
For about one third of the glucose measurements done by
one of the two portable glucose meters and for almost
100% of the glycaemia results obtained by the ABL 735
(one value missing), a simultaneous haematocrit value
measured by the ABL 735 was available. This enabled us
to investigate if haematocrit had an influence on accuracy
of the blood glucose measurement by the three POCT
systems.
Statistics
Statistics were performed using the software Analyse-it for
Microsoft Excel, version 2.20 (Analyse-it Software, Ltd.
http://www.analyse-it.com, 2009). Agreement between
methods was analysed using Passing & Bablok fits and
bias plots, with the difference between the compared
methods plotted against the reference method (modified
Bland–Altman). Performance of the different POCT methods
was obtained by ROC curve analysis.
A mixed linear regression was fitted to test the effect of
haematocrit on glucose measurement, allowing for the
constant to vary randomly across individuals. The significance
of the slope was tested by means of the Wald test. This was
done using the software STATA, version 10.1. A p value
<0.05 was considered statistically significant.
Results
Method comparison
For the 1-year study period, we identified a total of 1,324
paired glucose results fulfilling the inclusion criteria. The
results of glycaemia values covered a similar range of
glucose concentration in the three POCT groups (Table 2).
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Fig. 2 Bias plots for the three POCT glucose meters: difference of
glycaemia values between each of the three POCT systems and the
reference method plotted against the reference method with ISO
15197 limits representation
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Figure 1 shows the agreement between the three POCT
systems and the reference method. Over the whole range of
glucose values, the slopes were respectively 1.05, 1.04 and
1.00 for Elite XL, Contour and ABL 735, with intercept
values of −0.16, +0.46 and +0.40 mmol/L (A-1, B-1 and C-1
in Fig. 1). These values do change for Elite XL and Contour
if we focus on the low range of glycaemia values (≤5 mmol/
L), but remain identical for ABL 735 (A-2, B-2 and C-2 in
Fig. 1). All POCT systems showed a positive bias compared
to the reference method (Fig. 2a–c), ranging from
+0.03 mmol/L for Elite XL to +0.73 mmol/L for Contour,
whilst ABL 735 was intermediate (+0.46 mmol/L). In terms
of accuracy, Contour showed the highest proportion of
values outside the ISO 15197 limits (Fig. 2a–c). In our study
population, none of the three POCT methods achieved the
ISO accuracy criteria, with an overall degree of fulfilment of
only 83.5% for Elite XL, 62.6% for Contour and 92.8% for
ABL 735 instead of the demanded 95% (Table 3) [13].
Sensitivity and specificity
The goal of neonatal glycaemia screening is the detection of
asymptomatic hypoglycaemia which we defined as a
glucose value ≤2.5 mmol/L. Taking into account that
POCT glucometers tend to overestimate glycaemia values,
our actual clinical protocol defines that all glycaemia results
≤3.0 mmol/L must be checked with the reference method in
the central laboratory. Table 4 shows the measured
sensitivity and specificity for this cutoff value of
3.0 mmol/L and the calculated respective values for a
cutoff value of ≤2.5 mmol/L. For both cutoff limits, Elite
XL appeared to have the best sensitivity, but the worst
specificity of all tested devices. In order not to miss any
hypoglycaemia, meaning to reach a sensitivity of 1.0, a
cutoff value would be needed to be fixed at ≥5.7 mmol/L
for all three POCT systems (Table 4). This, however, is
clinically not feasible because far too many measurements
would demand a control in the central laboratory (specific-
ity of all three devices ≤0.40; Table 4). We then compared
the three methods at a threshold with a clinically reasonable
sensitivity of 0.94. The cutoff value would then be of
≤3.0 mmol/L for Elite XL, ≤3.5 mmol/L for Contour and
≤3.3 mmol/L for ABL 735 (Table 4).
Influence of haematocrit
In order to investigate the influence of haematocrit on
accuracy of the three POCT systems, we analysed the
bias (=difference between POCT and reference glucose
results) in relation to the simultaneously measured
capillary haematocrit. Table 2 shows sample size and
distribution of the haematocrit values for the three groups.
Whereas no change in agreement was found in relation to
haematocrit for Elite XL (slope 0.001, p = 0.89; Fig. 3a),
there was a statistically significant increasing difference
between Contour and the reference method with increas-
ing haematocrit (slope 0.040, p<0.001; Fig. 3b). In other
words, Contour showed an increasing overestimation of
Elite XL Contour ABL 735
Total samples (n) 472 532 320
Number of samples
With glycaemia ≤4.2 mmol/L 318 (67.4%) 314 (59.0%) 175 (54.7%)
With glycaemia >4.2 mmol/L 154 (32.6%) 218 (41.0%) 145 (45.3%)
ISO criteria fulfilled
For glycaemia ≤4.2 mmol/L 271/318 (85.2%) 193/314 (61.5%) 157/175 (89.7%)
For glycaemia >4.2 mmol/L 123/154 (79.9%) 140/218 (64.2%) 140/145 (96.6%)
For all glycaemia values 394/472 (83.5%) 333/532 (62.6%) 297/320 (92.8%)
Table 3 Degree of fulfilment of
the ISO 15197 accuracy criteria
Tolerated range for ISO criteria:
±0.8 mmol/L compared to the
reference method (hexokinase-
based) for values ≤4.2 mmol/L
and ±20% for glycaemia values
>4.2 mmol/L
Table 4 ROC analysis for the three POCT glucose meters
Elite XL Contour ABL 735
Sample size (n) 472 532 320
Prevalence of hypoglycaemia
(≤2.5 mmol/L measured by
the reference method)
30% 27% 19%
Area under the curve 0.90 0.94 0.96
(95% confidence interval) (0.87–0.93) (0.92–0.96) (0.93–0.99)
Cutoff ≤2.5 mmol/L
Sensitivity 0.86 0.43 0.55
Specificity 0.80 0.98 1.00
Cutoff ≤3.0 mmol/L
Sensitivity 0.94 0.82 0.89
Specificity 0.67 0.89 0.95
Sensitivity of 1.0
Minimal cutoff (mmol/L) ≤5.7 ≤6.2 ≤5.8
Specificity 0.31 0.40 0.34
Sensitivity of 0.94
Cutoff (mmol/L) ≤3.0 ≤3.5 ≤3.3
Specificity 0.67 0.84 0.89
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glucose values in high haematocrit blood samples by
0.4 mmol/L per 10% haematocrit increase. Although
statistically significant, the increasing difference measured
for ABL 735 (slope 0.007, p<0.05) is too small to be of
clinical relevance (Fig. 3c).
Discussion
Blood glucose measurements are frequently performed in
newborn infants, mainly to detect hypoglycaemia during
their first postnatal days. Handheld POCT glucometers
are very popular due to the easy and rapid assessment of
glycaemia in a small amount of blood, but it is ethically
quite challenging to test the accuracy of new glucometers
in the neonatal population in randomised trials because
of their small circulating blood volume. Thanks to a
performing DAS, we were able to screen retrospectively
all glucose measurements performed in our NICU over a
1-year period to identify paired glucose results measured
in parallel on the same capillary blood sampling by one
of three POCT methods as well as by the reference
hexokinase method. To our surprise, none of the three
tested POCT systems reached the ISO accuracy criteria,
with a degree of fulfilment of only 62.6% (Contour),
83.5% (Elite XL) and 92.8% for the blood gas analyser
(ABL 735) instead of the required 95% [13]. These
results contrast with those of the single neonatal trial
performed with this latest generation of Contour devices
(results in 5 s, FAD as coenzyme) in which the ISO
criteria seemed to be fulfilled [5]. However, for the
samples with low glucose concentration (≤4.2 mmol/L),
the plasma referenced Contour did not reach either the
demanded limit of agreement (93.8%), with inaccuracy
being even higher (90%) in very low glycaemia values
(≤2.8 mmol/L) [5]. The discrepancy between the two
studies could be explained, at least partly, by procedure
differences like the different types of reference methods
(glucose oxidase-based vs. hexokinase-based). Further-
more, in the study by Dietzen et al., anticoagulated blood
from a heparinised tube was taken for glucose measure-
ment with Contour just before plasma separation and
measurement with the reference method. Due to our
study design with a more clinically oriented approach,
we had a higher delay between the two measurements,
one on native whole blood with POCT device on clinical
ward and the other on plasma in the central laboratory of
the hospital. We limited by our inclusion criteria the total
turnaround time to 60 min, including transport of blood
sample in tubes coated with either fluoride or lithium
heparinate to the central laboratory, its reception, plasma
separation, glucose measurement, validation and intro-
duction in the DAS. We are thus aware that until plasma
separation, glycaemia values may have decreased. How-
ever, Chan et al. [3] have shown that such a decrease does
not encompass 5% of the initial glucose values when
blood remains in a tube coated with fluoride or with
lithium heparinate for a total of 60 min. Additionally, as
treated the exact same way, differences between Elite XL
and Contour can’t neither be explained herewith.
Fig. 3 Effect of haematocrit on POCT glycaemia measurements:
difference of glycaemia values between each of the three POCT
devices and the reference method plotted against capillary haematocrit
with lines of the 95% confidence interval
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A method with a reasonably high sensitivity to detect
hypoglycaemic values is of utmost importance in neonates
as these episodes may remain clinically asymptomatic. In
the absence of a clear consensus about the limit of
hypoglycaemia in neonatology, we considered, in accor-
dance to Lucas et al., values of <2.6 mmol/L as
hypoglycaemic because these episodes are associated with
an increased risk for impaired long-term development, as
shown for preterm infants [6, 19]. Due to a significant
overestimation of glycaemia results shown for several
handheld POCT devices in different studies, real hypogly-
caemic episodes might be at risk to be missed with these
tools [2, 9, 21, 23, 25]. In order to define clinically relevant
and applicable limits for the use of these glucometers, we
tested with the help of ROC analysis different strategies
regarding sensitivity, specificity and cutoff values (Table 4).
Ideally, a glucose meter should have a sensitivity of 1.0 in
order not to miss any hypoglycaemia. To reach this goal, a
cutoff value would be needed for the three tested POCT
devices between 5.7 and 6.3 mmol/L, which is of no
clinical practicability. With a pragmatic acceptable sensi-
tivity of 0.94, we calculated a cutoff of ≤3.0 mmol/L for
Elite XL, ≤3.5 mmol/L for Contour and ≤3.3 mmol/L for
ABL 735 (Table 4). It is to be noticed that Contour with a
cutoff of ≤3.5 mmol/L would have a better specificity
(0.84) than Elite XL with a cutoff of ≤3.0 mmol/L (0.67).
Although ABL 735 would be a valuable alternative in terms
of accuracy, its drawback is its higher blood volume
requisite (35 µL instead of 2 µL).
Haematocrit has been described to interfere with blood
glucose measurements in various handheld POCT devices
[11, 12, 18, 30]. In accordance with other studies with Elite
XL in neonatal populations, we did not find any influence
of the haematocrit value on the accuracy of glucose
measurement [11, 12]. In contrast, for the newer glucom-
eter, Contour, we found a statistically significant bias with
increasing haematocrit. For every 10% increase of haema-
tocrit, glycaemia was increased by 0.4 mmol/L. A similar
haematocrit dependency, although to a lower degree, was
already described in the only existing trial report of the
Contour in the neonatal population [5].
In regards to these results, we concluded for our clinical
daily practice: (1) To stop the use of the glucometer
Contour as handheld POCT device. The company was
informed about our doubts and has since then discouraged
neonatologists in Switzerland to use this device anymore
for screening purposes of hypoglycaemia in newborn
patients. (2) Although not fully satisfactory because of its
low specificity, to return to the older generation of
glucometer Elite XL using a cutoff limit of ≤3.0 mmol/L.
(3) To change our actual organization and infrastructure to
allow POCT glucose measurements on the ABL 735 with
the 35 μL capillaries. (4) To launch in the future a
prospective trial to test new handheld POCT devices with
the specific focus on their neonatal use.
We emphasise the demand that every new POCT device for
glucose measurement needs to be carefully tested in clinical
trials before its routine use. The validation should be done
taking into account the specific characteristics of the patient
population (e.g. neonates) and should be focused on the
question of interest (e.g. screening for hypoglycaemia or
follow-up of insulin treatment). A close collaboration between
clinicians, hospital laboratories and companies in such trials is
very important.
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